- Home
- ARTW vs INAB Comparison
ARTW vs INAB Comparison
Compare ARTW & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- INAB
- Stock Information
- Founded
- ARTW 1956
- INAB 2016
- Country
- ARTW United States
- INAB United States
- Employees
- ARTW N/A
- INAB N/A
- Industry
- ARTW Industrial Machinery/Components
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARTW Industrials
- INAB Health Care
- Exchange
- ARTW Nasdaq
- INAB Nasdaq
- Market Cap
- ARTW 12.5M
- INAB 10.6M
- IPO Year
- ARTW N/A
- INAB 2021
- Fundamental
- Price
- ARTW $2.50
- INAB $2.10
- Analyst Decision
- ARTW
- INAB Strong Buy
- Analyst Count
- ARTW 0
- INAB 2
- Target Price
- ARTW N/A
- INAB $108.00
- AVG Volume (30 Days)
- ARTW 60.0K
- INAB 63.9K
- Earning Date
- ARTW 10-07-2025
- INAB 11-10-2025
- Dividend Yield
- ARTW N/A
- INAB N/A
- EPS Growth
- ARTW N/A
- INAB N/A
- EPS
- ARTW 0.49
- INAB N/A
- Revenue
- ARTW $24,079,949.00
- INAB N/A
- Revenue This Year
- ARTW N/A
- INAB N/A
- Revenue Next Year
- ARTW N/A
- INAB N/A
- P/E Ratio
- ARTW $6.61
- INAB N/A
- Revenue Growth
- ARTW N/A
- INAB N/A
- 52 Week Low
- ARTW $1.43
- INAB $1.91
- 52 Week High
- ARTW $4.71
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- ARTW 42.61
- INAB 45.37
- Support Level
- ARTW $2.30
- INAB $2.04
- Resistance Level
- ARTW $2.67
- INAB $2.15
- Average True Range (ATR)
- ARTW 0.26
- INAB 0.12
- MACD
- ARTW -0.02
- INAB -0.01
- Stochastic Oscillator
- ARTW 22.02
- INAB 12.75
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.